New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

Valentina Mercurio; Anna Bianco; Giacomo Campi; Alessandra Cuomo; Nermin Diab; Angela Mancini; Paolo Parrella; Mario Petretta; Paul M Hassoun; Domenico Bonaduce

doi:10.2174/0929867325666180201095743

New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension

Curr Med Chem. 2019;26(16):2844-2864. doi: 10.2174/0929867325666180201095743.

Authors

Affiliations

¹ Johns Hopkins University, Division of Pulmonary and Critical Care Medicine, Baltimore, MD, United States.
² Federico II University, Department of Translational Medical Sciences, Naples, Italy.
³ University of Ottawa, Department of Medicine, Ottawa, ON, Canada.

PMID: 29421995
DOI: 10.2174/0929867325666180201095743

Abstract

Despite recent advances in Pulmonary Arterial Hypertension (PAH) treatment, this condition is still characterized by an extremely poor prognosis. In this review, we discuss the use of newly-approved drugs for PAH treatment with already known mechanisms of action (macitentan), innovative targets (riociguat and selexipag), and novel therapeutic approaches with initial up-front combination therapy. Secondly, we describe new potential signaling pathways and investigational drugs with promising role in the treatment of PAH.

Keywords: Pulmonary arterial hypertension; gene therapy; immunity; inflammation; initial combination therapy; macitentan; metabolism; pulmonary arterial denervation; riociguat; selexipag; serotonin..

Publication types

Review

MeSH terms

Animals
Endothelin Receptor Antagonists / pharmacology
Genetic Therapy
Humans
Hypertension, Pulmonary / drug therapy
Hypertension, Pulmonary / therapy*
Immunotherapy
Phosphodiesterase 5 Inhibitors / pharmacology
Signal Transduction / drug effects*

Substances

Endothelin Receptor Antagonists
Phosphodiesterase 5 Inhibitors